Bengaluru-based Remidio Innovative Solutions, a pioneer in AI-enabled ophthalmic technology, has unveiled Neubo 130 — an advanced ultra-widefield neonatal retinal imaging system designed to transform early diagnosis of retinal conditions such as Retinopathy of Prematurity (ROP).
With over three million premature births annually in India, the demand for timely retinal screening far exceeds the availability of ROP specialists. Neubo 130 bridges this critical gap by combining cutting-edge optical engineering with edge AI, enabling real-time detection of ROP even without internet connectivity.
Featuring a 130° field of view, through-the-lens illumination, and light-shaping technology, the device delivers uniform retinal brightness and exceptional peripheral visualization — essential for detecting subtle retinal changes in newborns that can determine sight-saving interventions.
Consistent peripheral detail with uniform illumination and minimal glare.
Small-pupil imaging capability for pupils ≥3 mm.
Instant and private bedside triage using offline AI for ROP and plus-disease detection, reducing missed diagnoses.
Panoramic composite imaging with automated montage for fewer retakes.
Collaborative care ready, with secure telemedicine and cloud integration for review and referral.
Weighing under 500g and delivering 2.4MP high-resolution imaging, Neubo 130 is purpose-built for hospital and NICU environments, aligning with Remidio’s mission to make eye care more accessible, affordable, and scalable — from tertiary hospitals to Special Newborn Care Units (SNCUs).